Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What’s the Evidence?

Abstract

Schizophrenia is a disabling, chronic psychiatric disorder with a prevalence rate of 0.5–1% in the general population. Symptoms include positive (e.g., delusions, hallucinations), negative (e.g., blunted affect, social withdrawal), as well as cognitive symptoms (e.g., memory and attention problems). Although 75–85% of patients with schizophrenia report cognitive impairments, the underlying neuropharmacological mechanisms are not well understood and currently no effective treatment is available for these impairments. This has led to the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative, which established seven cognitive domains that are fundamentally impaired in schizophrenia. These domains include verbal learning and memory, visual learning and memory, working memory, attention and vigilance, processing speed, reasoning and problem solving, and social cognition. Recently, a growing number of studies have been conducted trying to identify the underlying neuropharmacological mechanisms of cognitive impairments in schizophrenia patients. Specific cognitive impairments seem to arise from different underlying neuropharmacological mechanisms. However, most review articles describe cognition in general and an overview of the mechanisms involved in these seven separate cognitive domains is currently lacking. Therefore, we reviewed the underlying neuropharmacological mechanisms focusing on the domains as established by the MATRICS initiative which are considered most crucial in schizophrenia.

Cognition and Related Neural Findings on Methamphetamine Use Disorder: Insights and Treatment Implications From Schizophrenia Research

“…A metaanalysis revealed that medication targeting the cholinergic system result in marginal improvement in verbal and spatial learning and memory (154). Preliminary evidence also suggest that oxytocin may improve social cognition and verbal learning and memory (155), but the efficacy of such intervention has proven to be inconclusive and more research is still needed (101).…”

MK-801-induced impairments on the trial-unique, delayed nonmatching-to-location task in rats: effects of acute sodium nitroprusside

“…In contrast, negative symptoms include social withdrawal and anhedonia, while cognitive symptoms involve deficits in attention, working memory, and impulse control (Lewis et al 2005). To date, no available treatment or combination of treatments reduces symptom presentation across all three domains (Vingerhoets et al 2013). Importantly, cognitive symptoms are highly indicative of patient functional outcome, including community functioning and interpersonal interactions, implicating them in patient quality of life (Bhagyavathi et al 2015).…”

Comparing the effects of subchronic phencyclidine and medial prefrontal cortex dysfunction on cognitive tests relevant to schizophrenia

“…It is becoming increasingly clear that the development of treatments for the cognitive symptoms of schizophrenia requires urgent attention (Minzenberg and Carter 2012;Schaefer et al 2013;Vingerhoets et al 2013). To achieve this aim we need valid animal models of the cognitive impairments in schizophrenia (Nestler and Hyman 2010).…”